newsfilter
← Latest News
Business Wire·

Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Follow-up Scans Show Continued Stable Disease in First Patient Cohort Company to Apply for FDA Fast Track Designation Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces consistent favorable